Back to top

Articles

  /  Publications   /  Articles (Page 4)

Gustavo Werutsky, Bruno Hochhegger, José Antônio Lopes de Figueiredo Pinto, Jeovany Martínez-Mesa, Mara Lise Zanini, Eduardo Herz Berdichevski, Eduardo Vilas, Vinícius Duval da Silva, Maria Teresa Ruiz Tsukazan, Arthur Vieira, Leandro Genehr Fritscher, Louise Hartmann, Marcos Alba, Guilherme Sartori, Cristina Matushita, Vanessa Bortolotto, Rayssa Ruszkowski do Amaral, Luís Carlos Anflor Junior, Facundo Zaffaroni, Carlos H. Barrios, Márcio Debiasi and Carlos Cezar Frietscher

Vladmir C. Cordeiro de Lima, Clarissa S. Baldotto, Carlos H. Barrios, Eldsamira M. Sobrinho, Mauro Zukin, Clarissa Mathias, Facundo Zaffaroni, Rodrigo C. Nery, Gabriel Madeira, Alex V. Amadio, Juliano C. Coelho, Guilherme Geib, Maria Fernanda Simões, and Gilberto Castro Jr

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Be?e N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.